U.S. lawmakers attempting to cut the cost of insulin for more than a million Americans to $35 per month are unlikely to succeed as November elections draw near and complicate bipartisan support, health policy and political experts say.
U.S. Senate Majority Leader Chuck Schumer said on March 22 he intends to hold votes this spring on a bill that would cap the cost of insulin, a life-sustaining diabetes drug.
This extraordinary March and April – marked by rising numbers of Covid-19 cases and fatalities, suffering for patients and families, courageous efforts by clinicians, restricted social interaction, business closings, massive unemployment – has battered our healthcare system and economy. Here are a few early thoughts on how the evolving pandemic has changed the outlook for health policy after the November elections.
